ESR1 and breast carcinoma: The effects of RANTES and IL-6 co-expression on the phenotype of breast cancer cells were more marked in MCF-7 cells, a poorly aggressive ER positive luminal cell line, as compared with the highly aggressive basal MDA-MB-231 cell line.